论文部分内容阅读
目的 比较进展期胃癌术后腹腔化疗和静脉化疗的临床疗效。方法 将 68例进展期胃癌术后化疗按前瞻、随机、对照的原则分为治疗组 (腹腔化疗 ) 3 3例及对照组 (静脉化疗 ) 3 5例 ,比较两组治疗的不良反应发生率、腹腔内复发率、肝转移率、3年生存率的差异。结果 治疗组胃肠反应率、骨髓抑制率、腹腔内复发率、肝转移率、3年无瘤生存率、3年生存率分别为 12 .1%、9.0 %、18.1%、12 .1%、2 3 .6%、5 4.5 %。对照组胃肠反应率、骨髓抑制率、腹腔内复发率、肝转移率、3年无瘤生存率、3年生存率分别为 91.3 %、85 .7%、60 .0 %、3 7.1%、12 .8%、3 4.3 %。结论 与静脉化疗比较 ,进展期胃癌术后腹腔化疗的不良反应发生率、腹腔内复发率、肝转移率、3年生存率率降低 ,差异有显著性 (P <0 .0 5 )。
Objective To compare the clinical efficacy of intraperitoneal chemotherapy and intravenous chemotherapy after advanced gastric cancer. Methods According to the prospective, randomized and controlled principles of postoperative chemotherapy in 68 patients with advanced gastric cancer, 33 patients in the treatment group (intraperitoneal chemotherapy) and 35 in the control group (intravenous chemotherapy) were divided into two groups. The incidence of adverse reactions, Intraperitoneal recurrence rate, liver metastasis rate, 3-year survival rate difference. Results The gastrointestinal response rate, bone marrow suppression rate, intraperitoneal recurrence rate, liver metastasis rate, 3-year disease-free survival rate and 3-year survival rate were 12.1%, 9.0%, 18.1%, 12.1% 23.6%, 4.55%. The gastrointestinal reaction rate, bone marrow suppression rate, intraperitoneal recurrence rate, liver metastasis rate, 3-year disease-free survival rate and 3-year survival rate were 91.3%, 85.7%, 60.0%, 31.1% 12.8%, 3 4.3%. Conclusions Compared with intravenous chemotherapy, the incidence of adverse reactions, intraperitoneal recurrence rate, hepatic metastasis rate and 3-year survival rate of patients with advanced gastric cancer after operation were significantly lower (P <0.05).